BRIEF-Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces Its Novel Inhibitors Show Promising In Silico Activity Against Measles And Related Viruses

Reuters

2025/03/26

BRIEF-Salarius Pharmaceuticals Merger Partner, Decoy <a href="https://laohu8.com/S/LENZ">Therapeutics</a>, Announces Its Novel Inhibitors Show Promising In Silico Activity Against Measles And Related Viruses

March 26 (Reuters) - Salarius Pharmaceuticals Inc SLRX.O:

SALARIUS PHARMACEUTICALS MERGER PARTNER, DECOY THERAPEUTICS, ANNOUNCES ITS NOVEL INHIBITORS SHOW PROMISING IN SILICO ACTIVITY AGAINST MEASLES AND RELATED VIRUSES

Source text: ID:nGNX2Pm53f

Further company coverage: SLRX.O

((Reuters.Briefs@thomsonreuters.com;))

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2522749568"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2522749568\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2522749568?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-26 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522749568","market":"us","top_or_hot":-1,"title":"BRIEF-Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces Its Novel Inhibitors Show Promising In Silico Activity Against Measles And Related Viruses","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Salarius Pharmaceuticals Merger Partner, Decoy <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Announces Its Novel Inhibitors Show Promising In Silico Activity Against Measles And Related Viruses</title></head><body><p><span>March 26 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/SLRX\">Salarius Pharmaceuticals Inc</a> <span>SLRX.O</span>:</p><ul><li><p>SALARIUS PHARMACEUTICALS MERGER PARTNER, DECOY THERAPEUTICS, ANNOUNCES ITS NOVEL INHIBITORS SHOW PROMISING IN SILICO ACTIVITY AGAINST MEASLES AND RELATED VIRUSES</p></li></ul><p>Source text: <span>ID:nGNX2Pm53f</span></p><p>Further company coverage: <span>SLRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces Its Novel Inhibitors Show Promising In Silico Activity Against Measles And Related Viruses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces Its Novel Inhibitors Show Promising In Silico Activity Against Measles And Related Viruses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-26 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Salarius Pharmaceuticals Merger Partner, Decoy <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Announces Its Novel Inhibitors Show Promising In Silico Activity Against Measles And Related Viruses</title></head><body><p><span>March 26 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/SLRX\">Salarius Pharmaceuticals Inc</a> <span>SLRX.O</span>:</p><ul><li><p>SALARIUS PHARMACEUTICALS MERGER PARTNER, DECOY THERAPEUTICS, ANNOUNCES ITS NOVEL INHIBITORS SHOW PROMISING IN SILICO ACTIVITY AGAINST MEASLES AND RELATED VIRUSES</p></li></ul><p>Source text: <span>ID:nGNX2Pm53f</span></p><p>Further company coverage: <span>SLRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUABTP6MC:1","article_id":"2522749568","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522749568","pubTimestamp":1742990543,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces Its Novel Inhibitors Show Promising In Silico Activity Against Measles And Related VirusesMarch 26 (Reuters) - Salarius Pha","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技"},"translate_title":"简介-Salarius Pharmaceuticals合并合作伙伴Decoy Therapeutics宣布其新型抑制剂显示出针对麻疹和相关病毒的有希望的计算机活性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLRX":0.9},"content_text":"BRIEF-Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces Its Novel Inhibitors Show Promising In Silico Activity Against Measles And Related VirusesMarch 26 (Reuters) - Salarius Pharmaceuticals Inc SLRX.O:SALARIUS PHARMACEUTICALS MERGER PARTNER, DECOY THERAPEUTICS, ANNOUNCES ITS NOVEL INHIBITORS SHOW PROMISING IN SILICO ACTIVITY AGAINST MEASLES AND RELATED VIRUSESSource text: ID:nGNX2Pm53fFurther company coverage: SLRX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}